Indication
Active immunisation against H5N1 subtype of Influenza A virus in individuals 6 months of age and above. Aflunov should be used in accordance with official recommendations.
Loading your page…
Loading your page…
Influenza, Human;Immunization;Disease Outbreaks
Marketing Authorisation Holder: Seqirus S.r.l.
EMA Authorisation: 28/11/2010
INN: zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)
AI Drug & Interaction Analysis
Free account required
Ask Osler about Aflunov: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.